Curcumin and cancer: barriers to obtaining a health claim

Nutr Rev. 2015 Mar;73(3):155-65. doi: 10.1093/nutrit/nuu064. Epub 2015 Feb 13.

Abstract

Curcumin is a highly pleiotropic molecule found in the rhizomes of Curcuma longa (turmeric). It is responsible for the yellow color of turmeric and has been shown to inhibit the proliferation of cancer cells and to be of use in preventing or treating a number of diseases. Curcumin has been shown to modulate multiple cell-signaling pathways simultaneously, thereby mitigating or preventing many different types of cancers, including multiple myeloma and colorectal, pancreatic, breast, prostate, lung, head, and neck cancers, in both animal models and humans. Current therapeutic approaches using a single cancer drug for a single target can be expensive, have serious side effects, or both. Consequently, new approaches to the treatment and prevention of cancer, including the integration of curcumin as a viable treatment strategy where dysregulation of many pathways is involved, are warranted. A methodical review of the evidence was performed to evaluate the effects of curcumin in support of a health claim, as established through the regulatory framework of Health Canada, for a relationship between the consumption of curcumin and the prevention and treatment of cancer.

Keywords: cancer; curcumin; health claim; turmeric.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Curcuma / chemistry*
  • Curcumin* / chemistry
  • Curcumin* / pharmacology
  • Curcumin* / therapeutic use
  • Humans
  • Mice
  • Neoplasms* / drug therapy
  • Neoplasms* / prevention & control

Substances

  • Antineoplastic Agents
  • Curcumin